Dendritic cell-based cancer immunotherapy for colorectal Cancer

World Journal of Gastroenterology

Volumn 22, Issue 17, 2016, Pages 4275-4286

  Kajihara, Mikio ^a   Takakura, Kazuki ^a   Kanai, Tomoya ^a   Ito, Zensho ^a   Saito, Keisuke ^a   Takami, Shinichiro ^a   Shimodaira, Shigetaka ^b   Okamoto, Masato ^c   Ohkusa, Toshifumi ^d   Koido, Shigeo ^d  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cancer immunotherapy; Colorectal cancer; Cytotoxic T lymphocyte; Dendritic cell; Immunecheckpoint inhibitors

Indexed keywords

ALPHA INTERFERON; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FALIMAREV; KEYHOLE LIMPET HEMOCYANIN; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MESSENGER RNA; MUCIN 1; PEMBROLIZUMAB; PICIBANIL; POXVIRUS VECTOR; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROSTANOID; TUMOR ANTIGEN; WT1 PROTEIN; CD274 PROTEIN, HUMAN; MAGEA1 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; WT1 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL FUSION; CELL LYSATE; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MISMATCH REPAIR; MOLECULARLY TARGETED THERAPY; NATURAL KILLER CELL; PASSIVE IMMUNIZATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR CELL; TUMOR IMMUNITY; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANTIGENS, CD274; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; MELANOMA-SPECIFIC ANTIGENS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, CYTOTOXIC; WT1 PROTEINS;

EID: 84969919869     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i17.4275     Document Type: Review

References (91)

1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383: 1490-1502 [PMID: 24225001 DOI:10.1016/s0140-6736(13)61649-9].
2. Kerr D. Clinical development of gene therapy for colorectal cancer. Nat Rev Cancer 2003; 3: 615-622 [PMID: 12894249 DOI:10.1038/nrc1147].
3. Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, Arihiro S, Arakawa H, Okamoto M, Gong J, Tajiri H. Immunotherapy for colorectal cancer. World J Gastroenterol 2013; 19: 8531-8542 [PMID: 24379570 DOI:10.3748/wjg.v19.i46.8531].
4. Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, Watanabe M, Yanaga K, Fujise K, Tajiri H, Gong J, Toda G. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 2005; 11: 7891-7900 [PMID: 16278414 DOI:10.1158/1078-0432.CCR-05-1330].
5. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000; 6: 24-33 [PMID: 10656428].
6. Berinstein NL. Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review. J Clin Oncol 2002; 20: 2197-2207 [PMID: 11956282].
7. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, Kishimoto T, Sugiyama H. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194-204 [PMID: 10189890].
8. Shimodaira S, Sano K, Hirabayashi K, Koya T, Higuchi Y, Mizuno Y, Yamaoka N, Yuzawa M, Kobayashi T, Ito K, Koizumi T. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer. Vaccines (Basel) 2015; 3: 1004-1018 [PMID: 26690485 DOI:10.3390/vaccines3041004].
9. Ajioka Y, Allison LJ, Jass JR. Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 1996; 49: 560-564 [PMID: 8813954].
10. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85: 713-720 [PMID: 11531257 DOI:10.1054/bjoc.2001.1974].
11. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y, Gu J. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005; 11: 1809-1814 [PMID: 15756003 DOI:10.1158/1078-0432.ccr-04-1365].
12. Sang M, Lian Y, Zhou X, Shan B. MAGE-A family: Attractive targets for cancer immunotherapy. Vaccine 2011; 29: 8496-8500 [PMID: 21933694 DOI:10.1016/j.vaccine.2011.09.014].
13. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009; 15: 1086-1095 [PMID: 19188184 DOI:10.1158/1078-0432.ccr-08-2227].
14. Grizzi F, Bianchi P, Malesci A, Laghi L. Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol 2013; 19: 174-184 [PMID: 23345940 DOI:10.3748/wjg.v19.i2.174].
15. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013; 2: E71 [PMID: 24042735 DOI:10.1038/oncsis.2013.35].
16. Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, Mineno J, Shiku H, Nishida S, Sugiyama H, Tajiri H, Homma S. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother 2011; 60: 1289-1297 [PMID: 21607557 DOI:10.1007/s00262-011-1033-3.
17. Koido S, Homma S, Takahara A, Namiki Y, Komita H, Uchiyama K, Ito M, Gong J, Ohkusa T, Tajiri H. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. Immunotherapy 2012; 4: 5-7 [PMID: 22149993 DOI:10.2217/imt.11.150].
18. Al-Ejeh F, Darby JM, Brown MP. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors. PLoS One 2009; 4: E4630 [PMID: 19247485 DOI:10.1371/journal.pone.0004630].
19. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997; 18: 267-268 [PMID: 9190110 DOI:10.1016/S0167-5699(97)80020-5].
20. Steinman RM, Swanson J. The endocytic activity of dendritic cells. J Exp Med 1995; 182: 283-288 [PMID: 7629494].
21. Tanaka Y, Koido S, Ohana M, Liu C, Gong J. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J Immunol 2005; 174: 1274-1280 [PMID: 15661883].
22. Adam C, King S, Allgeier T, Braumüller H, Lüking C, Mysliwietz J, Kriegeskorte A, Busch DH, Röcken M, Mocikat R. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood 2005; 106: 338-344 [PMID: 15769894 DOI:10.1182/blood-2004-09-3775].
23. van Beek JJ, Wimmers F, Hato SV, de Vries IJ, Sköld AE. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination. Crit Rev Immunol 2014; 34: 517-536 [PMID: 25597314].
24. Wehner R, Dietze K, Bachmann M, Schmitz M. The bidirectional crosstalk between human dendritic cells and natural killer cells. J Innate Immun 2011; 3: 258-263 [PMID: 21411969 DOI:10.1159/000323923].
25. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426 [PMID: 17898760].
26. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332 [PMID: 9500607.
27. Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Gong J, Sugiyama H, Ohkusa T, Tajiri H. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res 2014; 20: 4228-4239 [PMID: 25056373 DOI:10.1158/1078-0432.ccr-14-0314].
28. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M. Clinical and immunologic evaluation of dendritic cellbased immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012; 41: 195-205 [PMID: 21792083 DOI: 10.1097/MPA.0b013e31822398c6].
29. Gilboa E, Vieweg J. Cancer immunotherapy with mRNAtransfected dendritic cells. Immunol Rev 2004; 199: 251-263 [PMID: 15233739 DOI:10.1111/j.0105-2896.2004.00139.x].
30. Mackensen A, Herbst B, Chen JL, Köhler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000; 86: 385-392 [PMID: 10760827].
31. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol 2011; 186: 1325-1331 [PMID: 21248270 DOI:10.4049/jimmunol.0902539.
32. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-561 [PMID: 9142127].
33. Gong J, Koido S, Calderwood SK. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev Vaccines 2008; 7: 1055-1068 [PMID: 18767954].
34. Cavallo F, Curcio C, Forni G. Immunotherapy and immunoprevention of cancer: Where do we stand? Expert Opin Biol Ther 2005; 5: 717-726 [PMID: 15934846 DOI:10.1517/14712598.5.5.717].
35. Giorda E, Sibilio L, Martayan A, Moretti S, Venturo I, Mottolese M, Ferrara GB, Cappellacci S, Eibenschutz L, Catricalà C, Grammatico P, Giacomini P. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells. Cancer Res 2003; 63: 4119-4127 [PMID: 12874016].
36. Koido S, Homma S, Takahara A, Namiki Y, Tsukinaga S, Mitobe J, Odahara S, Yukawa T, Matsudaira H, Nagatsuma K, Uchiyama K, Satoh K, Ito M, Komita H, Arakawa H, Ohkusa T, Gong J, Tajiri H. Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol 2011; 2011: 267539 [PMID: 21922022 DOI:10.1155/2011/267539].
37. Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H, Nagasaki E, Ito M, Ohkusa T, Gong J, Tajiri H. Regulation of tumor immunity by tumor/dendritic cell fusions. Clin Dev Immunol 2010; 2010: 516768 [PMID: 21048993 DOI:10.1155/2010/516768].
38. Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci 2015; 106: 945-950 [PMID: 25981182 DOI:10.1111/cas.12695].
39. Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013; 49: 2233-2242 [PMID: 23478000 DOI:10.1016/j.ejca.2013.02.015].
40. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, Danciu M, Bruneval P, Scripcariu V, Chevallier JM, Zinzindohoué F, Berger A, Galon J, Pagès F. Prognostic and predictive values of the immunoscore in patients with rectal cancez. Clin Cancer Res 2014; 20: 1891-1899 [PMID: 24691640 DOI:10.1158/1078-0432.ccr-13-2830].
41. Merika E, Saif MW, Katz A, Syrigos K, Morse M. Review. Colon cancer vaccines: An update. In Vivo 2010; 24: 607-628 [PMID: 20952724].
42. Quigley DA, Kristensen V. Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Mol Oncol 2015; 9: 2054-2062 [PMID: 26607741 DOI:10.1016/j.molonc.2015.10.003].
43. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, Yang AG, Wen WH. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One 2013; 8: E76012 [PMID: 24124529 DOI:10.1371/journal.pone.0076012].
44. Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One 2015; 10: E0131403 [PMID: 26114883 DOI:10.1371/journal.pone.0131403].
45. Zhao LW, Li C, Zhang RL, Xue HG, Zhang FX, Zhang F, Gai XD. B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. Acta Histochem 2014; 116: 1163-1168 [PMID: 25053455 DOI:10.1016/j.acthis.2014.06.003].
46. Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)- pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5: 1331-1338 [PMID: 10389916].
47. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, Boczkowski D, Proia A, Neidzwiecki D, Clavien PA, Hurwitz HI, Schlom J, Gilboa E, Lyerly HK. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21: 341-349 [PMID: 12901279].
48. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005; 11: 3017-3024 [PMID: 15837756 DOI:10.1158/1078-0432.ccr-04-2172].
49. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: A mechanism of action for clinical activity. Cancer Immunol Immunother 2006; 55: 1122-1131 [PMID: 16273350 DOI:10.1007/s00262-005-0089-3].
50. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines? Oncologist 2012; 17: 1256-1270 [PMID: 22907975 DOI:10.1634/theoncologist.2011-0122].
51. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, Miyazaki M, Kakita N, Higashitani K, Matsubara T, Hiramatsu N, Kasahara A, Takehara T, Hayashi N. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother 2011; 60: 1565-1575 [PMID: 21681375 DOI:10.1007/s00262-011-1051-1].
52. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98: 8809-8814 [PMID: 11427731 DOI:10.1073/pnas.141226398].
53. Itoh T, Ueda Y, Kawashima I, Nukaya I, Fujiwara H, Fuji N, Yamashita T, Yoshimura T, Okugawa K, Iwasaki T, Ideno M, Takesako K, Mitsuhashi M, Orita K, Yamagishi H. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24- restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002; 51: 99-106 [PMID: 11904734 DOI:10.1007/s00262-001-0257-z].
54. Liu KJ, Wang CC, Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Yang HY, Juang SH, Whang-Peng J. Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A∗0201 and HLA-A∗2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004; 10: 2645-2651 [PMID: 15102666].
55. Matsuda K, Tsunoda T, Tanaka H, Umano Y, Tanimura H, Nukaya I, Takesako K, Yamaue H. Enhancement of cytotoxic T-lymphocyte responses in patients with gastrointestinal malignancies following vaccination with CEA peptide-pulsed dendritic cells. Cancer Immunol Immunother 2004; 53: 609-616 [PMID: 14735319 DOI:10.1007/s00262-003-0491-7].
56. Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 2004; 24: 909-917 [PMID: 15010829].
57. Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, Ruers TJ, Adema GJ, Punt CJ. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests. Ann Oncol 2006; 17: 974-980 [PMID: 16600979 DOI:10.1093/annonc/mdl072].
58. Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother 2006; 55: 268-276 [PMID: 16034561 DOI:10.1007/s00262-005-0021-x].
59. Oji Y, Yamamoto H, Nomura M, Nakano Y, Ikeba A, Nakatsuka S, Abeno S, Kiyotoh E, Jomgeow T, Sekimoto M, Nezu R, Yoshikawa Y, Inoue Y, Hosen N, Kawakami M, Tsuboi A, Oka Y, Ogawa H, Souda S, Aozasa K, Monden M, Sugiyama H. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003; 94: 712-717 [PMID: 12901797].
60. Miyata Y, Kumagai K, Nagaoka T, Kitaura K, Kaneda G, Kanazawa H, Suzuki S, Hamada Y, Suzuki R. Clinicopathological significance and prognostic value of Wilms' tumor gene expression in colorectal cancer. Cancer Biomark 2015; 15: 789-797 [PMID: 26406403 DOI:10.3233/cbm-150521].
61. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-5337 [PMID: 19723653 DOI:10.1158/1078-0432.CCR-09-0737].
62. Oka Y, Sugiyama H. WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects. Immunotherapy 2010; 2: 591-594 [PMID: 20874639 DOI:10.2217/imt.10.58].
63. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol 2010; 40: 377-387 [PMID: 20395243].
64. Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. Oncoimmunology 2014; 3: E958950 [PMID: 25941581 DOI:10.4161/21624011.2014.958950].
65. Sadanaga N, Nagashima H, Mashino K, Tahara K, Yamaguchi H, Ohta M, Fujie T, Tanaka F, Inoue H, Takesako K, Akiyoshi T, Mori M. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7: 2277-2284 [PMID: 11489802].
66. Tanaka F, Haraguchi N, Isikawa K, Inoue H, Mori M. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep 2008; 20: 1111-1116 [PMID: 18949409].
67. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, Crocenzi TS, Cole DJ, Dessureault S, Hobeika AC, Osada T, Onaitis M, Clary BM, Hsu D, Devi GR, Bulusu A, Annechiarico RP, Chadaram V, Clay TM, Lyerly HK. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; 258: 879-886 [PMID: 23657083 DOI:10.1097/SLA.0b013e318292919e].
68. Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 2011; 17: 7164-7173 [PMID: 22068656 DOI:10.1158/1078-0432.ccr-11-0649].
69. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732-736 [PMID: 9485028].
70. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007; 30: 762-772 [PMID: 17893568 DOI:10.1097/CJI.0b013e318133451c].
71. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309-4317 [PMID: 10361129].
72. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumorand dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57: 1569-1577 [PMID: 18523771 DOI:10.1007/s00262-008-0536-z].
73. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165: 5713-5719 [PMID: 11067929].
74. Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999; 82: 121-124 [PMID: 10360830 DOI:10.1002/(SICI)1097-0215(19990702)82].
75. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001; 48: 347-351 [PMID: 11379307].
76. Kajihara M, Takakura K, Ohkusa T, Koido S. The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies. Immunotherapy 2015; 7: 1111-1122 [PMID: 26507578 DOI:10.2217/imt.15.73].
77. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: Evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol Immunother 2002; 51: 299-310 [PMID: 12111118 DOI:10.1007/s00262-002-0284-4].
78. Homma S, Kikuchi T, Ishiji N, Ochiai K, Takeyama H, Saotome H, Sagawa Y, Hara E, Kufe D, Ryan JL, Ohno T, Toda G. Cancer immunotherapy by fusions of dendritic and tumour cells and rh- IL-12. Eur J Clin Invest 2005; 35: 279-286 [PMID: 15816998].
79. Homma S, Sagawa Y, Ito M, Ohno T, Toda G. Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses. Clin Exp Immunol 2006; 144: 41-47 [PMID: 16542363 DOI:10.1111/j.1365-2249.2006.03029.x].
80. Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-9487 [PMID: 9689106].
81. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Ito M, Ohkusa T, Gong J, Tajiri H. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2: E24437 [PMID: 23762810 DOI:10.4161/onci.24437].
82. Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 2007; 56: 2003-2016 [PMID: 17333181 DOI:10.1007/s00262-007-0299-y].
83. Toh HC, Wang WW, Chia WK, Kvistborg P, Sun L, Teo K, Phoon YP, Soe Y, Tan SH, Hee SW, Foo KF, Ong S, Koo WH, Zocca MB, Claesson MH. Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients. Clin Cancer Res 2009; 15: 7726-7736 [PMID: 19996212 DOI:10.1158/1078-0432.ccr-09-1537].
84. Parsons R, Li GM, Longley MJ, Fang WH, Papadopoulos N, Jen J, de la Chapelle A, Kinzler KW, Vogelstein B, Modrich P. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993; 75: 1227-1236 [PMID: 8261516].
85. Timmermann B, Kerick M, Roehr C, Fischer A, Isau M, Boerno ST, Wunderlich A, Barmeyer C, Seemann P, Koenig J, Lappe M, Kuss AW, Garshasbi M, Bertram L, Trappe K, Werber M, Herrmann BG, Zatloukal K, Lehrach H, Schweiger MR. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One 2010; 5: E15661 [PMID: 21203531 DOI:10.1371/journal.pone.0015661].
86. Aguiar PN, Tadokoro H, Forones NM, de Mello RA. MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. Immunotherapy 2015; 7: 1133-1134 [PMID: 26568256 DOI:10.2217/imt.15.84].
87. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Jen J, Hamilton SR. Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-816 [PMID: 8484121].
88. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Nakagawa H, Sotamaa K, Prior TW, Westman J, Panescu J, Fix D, Lockman J, Comeras I, de la Chapelle A. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005; 352: 1851-1860 [PMID: 15872200 DOI:10.1056/NEJMoa043146].
89. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA. PD-1 Blockade in Tumors with Mismatch- Repair Deficiency. N Engl J Med 2015; 372: 2509-2520 [PMID: 26028255 DOI:10.1056/NEJMoa1500596].
90. Lee V, Le DT. Efficacy of PD-1 blockade in tumors with MMR deficiency. Immunotherapy 2016; 8: 1-3 [PMID: 26643016 DOI:10.2217/imt.15.97].
91. Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res 2010; 16: 6019-6028 [PMID: 20924130 DOI:10.1158/1078-0432.ccr-10-1966].